Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum

Table 1

Comparison of antibody-based assay results for megakaryocyte potentiating factor.

Report	Manufacturer of assay	Antibodies used	Sensitivity for MM	Specificity
				cf benign and controls	cf malignancy	Overall
Onda et al., 2006 [12]	Authors	MPF25 and MPF49	51/56 (91%)	0/70	—	100%
Shiomi et al., 2006* [13]	Authors	7E7 and PoAb-282	7/7	0/13	0/3	100%
Shiomi et al., 2008* [14]	Authors	7E7 and PoAb-282	29/39 (74%)	—	—	87% (46/356)
Shiomi et al., 2008* [14]	Authors	7E7 and 16K16	28/39 (72%)	—	—	96% (14/356)
Creaney et al., 2008 [11]	IBL, Japan	7E7 and PoAb-282	21/66 (32%)	3/70	2/30	95%
Iwahori et al., 2008 [15]	Authors	20-10 and 41-28	20/27 (74%)	1/47	14/82	88%
Hollevoet et al., 2010* [16]	MBL, Japan	20-10 and 41-28	58/85 (68%)	10/359	3/63	97%

∗Values extrapolated from the presented data.
IBL: Immuno-Biologic Laboratories (Gunma, Japan).
MBL: Medical & Biological Laboratories (Nagano, Japan).